The Magpie Trial: A randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months
Yu, L. M.
De Sagastizabal, M.
Montes, Varela D.
Ortiz De Speranza, B.
Barros, Santos C.
Breto, Garcia A.
Fuentes, Ramirez A.
Garcia, Miras R.
Abd El-Kreem, H.
Padmini, Jasper M.
Ruby, Faiz N.
Van Zyl, J.
Jacobson, S. L.
MetadataShow full item record
Objective: To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia. Design: Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998-2001 ISRCTN 86938761), which compared magnesium sulphate with placebo. Setting: Follow-up of children born at 125 centres in 19 countries across five continents. Population: A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted. Methods: Assessment by questionnaire, with interview and neurodevelopmental testing of selected children. Main outcome measures: Death or neurosensory disability at age of 18 months. Results: Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities. Conclusions: The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months. © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology.
Please cite this item using this persistent URLhttp://hdl.handle.net/10019.1/13447
Showing items related by title, author, creator and subject.
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J.; Opal, S.; Laterre, P-F.; Abraham, E.; Francois, B.; Wittebole, X.; Lowry, S.; Dhainaut, J-F.; Warren, B.; Dugernier, T.; Lopez, A.; Sanchez, M.; Demeyer, I.; Jauregui, L.; Lorente, J. A.; McGee, W.; Reinhart, K.; Kljucar, S.; Souza, S.; Pribble, J. (2004)Objective: Platelet-activating factor (PAF) and structurally-related oxidized phospholipids are proinflammatory mediators in systemic inflammatory states such as severe sepsis. The enzyme platelet-activating factor ...
Inherited and acquired thrombophilias and poor pregnancy outcome: Should we be treating with heparin? Gebhardt G.S.; Hall D.R.; Gebhardt G.S.; Hall D.R. (2003)Purpose of review: The most important acquired thrombophilia related to poor pregnancy outcome is probably antiphospholipid syndrome. Inherited thrombophilias that have been implicated in venous thromboembolism and poor ...
Patient-controlled epidural analgesia versus continuous infusion for labour analgesia: A meta-analysis Van Der Vyver M.; Halpern S.; Joseph G. (2002)Background. Patient-controlled epidural analgesia (PCEA) is a relatively new method of maintaining labour analgesia. There have been many studies performed that have compared the efficacy of PCEA with continuous epidural ...